发育过程中肝脏血管活性肠肽及其受体量的变化

已有的研究观察到,胚胎肝脏中血管活性肠肽(vasoactiveintestinalpolypeptide,VIP)及其受体(vasoactiveintesti-nalpolypeptidereceptor,VIPR)与造血干细胞生长和肝脏发育有关。本研究旨在了解发育过程中肝VIP及VIPR量的动态变化。采用放射免疫分析法、生物分子相互作用系统和RT-PCR等技术检测了各发育阶段大鼠肝组织VIP浓度、VIP受体结合量及VIP受体表达亚型,实验观察到胎鼠和新生鼠肝脏VIP浓度显著低于未成年鼠及成年鼠肝脏VIP浓度(P<0.05)。发育尚未成熟时(胎鼠、新生鼠、未成年鼠),肝VIPR表达均明显高于成年鼠(P<0.05),表明大鼠在发育过程中肝脏VIP与VIP受体量呈相反的变化趋势。大鼠发育各时期,肝脏均表达VIPR-1。这些结果部分解释了肝脏发育、肝脏造血转移等重要生理现象。     

猕猴发育过程中肠肝组织生长抑素及其受体表达演变规律

探讨在猕猴发育过程中生长抑素(somatostatin,SST)及其受体在肠肝组织的演变规律。通过手术途径获得胚胎6月、新生2 d、新生45 d和成年猕猴的回肠、肝脏、门静脉和外周血等标本。应用放射免疫分析法测定各标本中的SST含量; 通过免疫组化方法观察SST在肠、肝组织内的分布;利用原位杂交检测SST受体2(somatostatin receptor 2,SSTR2)的表达。结果显示:(1)胚胎6月的猕猴,小肠内SST含量为(27．3±16．6)ng／mg蛋白;黏膜隐窝处SST呈弱阳性染色,肌层 SST染色阴性。在发育过程中,小肠内SST含量逐渐增加,成年期时达最高水平(120．1±35．3)ng／mg蛋白,较胚胎6月显著增加(P<0．01)。(2)成年小肠黏膜隐窝处及肌间神经丛SST呈强阳性染色。(3)胚胎6月,小肠粘膜上皮可见大量SSTR2 表达,成年时SSTR2表达下调,且主要定位于腺上皮隐窝处;胚胎及新生期肌层SSTR2染色阴性,成年时小肠肌间神经丛则可见阳性SSTR2染色。(4)肝脏在发育过程中SST及SSTR2含量逐渐降低;发育的各个时期,小肠组织的SST含量均明显高于肝脏组织含量,门静脉SST水平也始终高于外周血。总之,位于小肠黏膜隐窝处的SST和SSTR2随着发育逐渐增加,来自肠道的SST进入门静脉后迅速被降解。SST阳性的肠肌间神经丛仅在发育成熟后才出现。     

血管活性肠肽对支气管上皮细胞趋化迁移的影响及机制

为探讨肺内神经肽在气道损伤修复中的作用 ,采用blind wellBoydenchamber测定原代培养的支气管上皮细胞 (bronchialepithelialcells,BEC)趋化性 ,观察血管活性肠肽 (vasoactiveintestinalpeptide ,VIP)对BEC趋化迁移的影响及其机制 ,并测定经热应激后BEC分泌VIP及表达VIP受体 (vasoactiveintestinalpeptidereceptor,VIPR)的变化。结果显示 :(1)以胰岛素作为趋化因子所建立的BEC趋化性测定方法稳定 ,重现性好 (r =0 970 3,P <0 0 1) ;(2 )VIP (0 0 0 1～ 1μmol/L)均显示剂量依赖性地增强BEC的趋化迁移 ,其效应可被钙调蛋白阻断剂及蛋白激酶C阻断剂有效地抑制 (P <0 0 1) ;(3) 4 2℃、30min热应激后BEC分泌VIP (P <0 0 1)及表达VIPR明显增加 (P <0 0 5 )。实验表明 :肺内神经肽VIP可增强BEC的趋化迁移 ,其细胞内信号转导途径与钙调蛋白及蛋白激酶C有关。而热应激时VIP及VIPR的高表达进一步提示局部微环境的VIP可能是气道上皮损伤修复网络中的重要分子     

肠易激综合征大鼠模型的复制与评价

目的建立肠易激综合征(IBS)大鼠模型,为实验药理学提供方法。方法采用复合因素诱导大鼠建立IBS模型,测定模型大鼠体重、摄食量、排便情况、自主运动量、胃排空率和肠推进率,分析血清5-HT、血浆SP、VIP含量以及结肠匀浆5-HT、SP、VIP含量变化,测定血液生化指标,显微观察胃窦黏膜和横结肠黏膜组织形态改变。结果造模后各大鼠体重减轻、摄食量减少,排便量增多、出现稀便和无定形软便,自主运动量减少,胃排空率减小、肠推进率加快,血清5-HT含量升高、血浆SP和VIP含量均降低,结肠匀浆5-HT和SP、VIP含量升高(P0.05,P0.01),血液生化指标未见异常,胃窦黏膜和横结肠黏膜无明显形态改变;匹维溴铵15.0 mg/kg治疗30 d后,大鼠体重、摄食量增加,排便量减少、稀便减少,自主运动量接近正常,血清5-HT含量下降、血浆SP和VIP含量升高,结肠匀浆5-HT和SP、VIP含量下降。结论复合因素随机刺激能成功复制IBS大鼠模型,其病理生理特征与临床研究结果基本吻合。     

不同能量需求的棕色田鼠胃肠道一氧化氮合酶和血管活性肠肽的分布

为研究在能量需求变化的情况下生理功能调节在消化道适应性变化中的地位,并探讨生理调节与消化道形态结构适应性变化的关系,采用NADPH-黄递酶（NDP）组织化学法、VIP免疫组织化学法和整装铺片技术对哺乳和非哺乳雌性棕色田鼠及雄性棕色田鼠胃肠道管壁肌间神经丛和黏膜下神经丛一氧化氮合酶（Nitricoxidesynthase,NOS）和血管活性肠肽（Vasoactive intestinal peptide,VIP）阳性神经元的分布进行观察。结果显示：哺乳和非哺乳雌性棕色田鼠及雄性棕色田鼠NOs阳性神经元分布于肌间神经丛,VIP分布于黏膜下神经丛,未观察到共染现象。NOS和VIP阳性神经元在哺乳雌性棕色田鼠胃及小肠前段的肌间神经丛和黏膜下神经丛的分布显著高于非哺乳雌鼠和雄鼠,而在回肠、盲肠和结肠差异不显著。由此说明,不同繁殖状态下,能量需求的不同促使消化道发生适应性变化,首先是生理功能及其调节机制的变化。同时提示消化道适应策略与消化道各段生理功能及能量胁迫程度有关[动物学报51（5）：830—839,2005]。     

血管活性肠肽对脑缺血大鼠血清S100β的影响

目的:明确血管活性肠肽(VIP)对脑缺血后血清S100β的影响,探讨VIP的神经保护机制.方法:在SD大鼠侧脑室内注射VIP后,采用大脑中动脉线栓法诱导建立暂时性局部脑缺血模型,双抗夹心ELISA检测血清中S100β的含量.结果:注射VIP后大鼠脑缺血后1天和3天血清S100β含量较对照组显著降低(P<0.05),而7天血清S100β含量与对照组比较无显著性差异.结论:VIP能明显减少脑缺血后早期血清中S100β的含量,可能是其神经保护作用机制之一.     

血管活性肠肽对脓毒性休克大鼠肝损伤的保护作用

采用盲肠结扎穿孔(cecal ligation and puncture,CLP)法制备脓毒性休克大鼠模型,探讨血管活性肠肽(vasoactive intestinal peptide,VIP)对脓毒性休克大鼠肝损伤的保护作用及其可能机制.将48只雄性SD大鼠随机分成4组:假手术组(SO,n=12)、CLP组(n=12)、VIP组(n=12)和生理盐水组(NS,n=12).VIP组大鼠在行CLP术后即刻给予6 nmol VIP,应用酶联免疫吸附试验(ELISA)检测各组大鼠血清谷丙转氨酶ALT和谷草转氨酶AST水平,同时检测血清炎症因子:促炎因子肿瘤坏死因子-α(TNF-α),抑炎因子白介素-10(IL-10)的变化;取大鼠肝脏组织行病理检查.在6 h以后的各时间点,与NS组比较,VIP组TNF-α水平明显降低,IL-10水平持续升高,VIP组AST和ALT水平自12 h始明显降低,肝脏病理损伤明显改善.实验表明,VIP通过抑制促炎因子的生成并促进抗炎因子的产生在大鼠脓毒性休克肝损伤中发挥保护作用.     

血管活性肠肽与乙酰胆碱在自主神经内共存问题的探讨（综述）

近年的实验曾指出血管活性肠肽(VIP)与乙酰胆碱(ACh)在自主神经中共存共释,并随之提出一系列新的受体理论。然而,因当时技术条件所限,上述实验并不准确。笔者去年首次证明.至少在脑血管中这两种神经递质在绝大多数副交感神经纤维中不共存。但是,VIP和胆碱能纤维之间却关系密切,使之不但可以直接,而且可以间接地相互影响脑血管张力。 单个神经元只产生和释放单一种神经递质的概念曾被普遍接受并被视为神经科学之经典学说。上述概念还被称为Dale法则。随着神经研究技术手段的发展,不少实验资料显示,电刺激神经纤维时,常可同时检测到多种神经递质被释放出来,从而使这一法则受到严峻挑战。某些形态学和生物化学实验结果更具体指出,一些肽类神经递质如血管活性肠肽(简称VIP)     

血管活性肠肽(VIP)在文昌鱼体内免疫组织化学定位的研究

本文用免疫组织化学技术首次发现VIP在文昌鱼体内有广泛分布。结果表明,VIP免疫阳性反应出现在消化道各部位,如中肠突、中肠前和后部以及后肠、神经系统、发育早期性腺以及口腔前庭两侧皮下组织中。     

血管活性肠肽对肺表面活性物质结合蛋白A表达的影响

目的:研究血管活性肠肽(VIP)对肺表面活性物质结合蛋白A(SP-A)表达的影响以及VIP调控SP-A表达的细胞内信号转导途径.方法:运用免疫组织化学和RT-PCR技术研究VIP对SP-A表达的影响;并进一步运用受体拮抗、蛋白激酶抑制、反义寡核苷酸阻断等手段探讨VIP促进SP-A表达的信号转导途径.结果:①VIP(10-8mol/L)促进肺泡Ⅱ型细胞(ATⅡ)细胞中的SP-A蛋白表达和提高肺组织SP-AmRNA含量:②VIP受体拮抗剂(10-6mol/L)可取消VIP(10-8mol/L)促进SP-A表达的效应;③蛋白激酶C抑制剂H7(10-5mol/L)和c-fos基因的反义寡核苷酸(9×10 6mol/L)均可阻断VIP促进SP-A表达的作用.结论:VIP通过其受体促进SP-A的表达,PKC及c-fos蛋白在介导VIP促进SP-A表达的细胞内信号转导过程中起重要作用.     

Role of vasoactive intestinal polypeptide (VIP) in the neurogenic vasodilatation of the portal vein in the rabbit

A coarse network of nerve fibres displaying immunoreactivity for vasoactive intestinal polypeptide (VIP) was found in the wall of the hepatic portal vein of the rabbit. Electrical field stimulation of the rabbit portal vein in vitro, in the presence of adrenergic and cholinergic blockade, caused a marked relaxation of the vessel and a release of VIP into the perfusate. Addition of VIP to the tissue bath elicited a concentration-dependent inhibition of the mechanical activity of the portal vein. The results suggest that VIP containing neurones might participate in the non-cholinergic, non-adrenergic vasodilatation of the portal vein in the rabbit.     

Degradation of vasoactive intestinal polypeptide by tissue homogenates

Extracts of liver, kidney and brain contain an enzyme that is highly specific for degradation of vasoactive intestinal polypeptide (VIP). The Michaelis constants (K_m's) appear to be nearly identical in all three tissues, averaging about 10^?5 mol/liter. The V_max for kidney and liver are about the same but that for cerebral cortex is about two-fold lower. Since the relative V_max in the three organs differ for insulin and VIP, it is concluded that it is unlikely that the same enzyme is responsible for the degradation of both peptides.     

Hepatic metabolism of vasoactive intestinal polypeptide (VIP) in the rat

Vasoactive intestinal polypeptide (VIP) is released into the portal circulation by a meal stimulus, but is rapidly cleared from plasma. Although it is known to bind to receptors on liver cells, the role of the liver in the clearance of VIP is not clearly defined. We therefore studied the disappearance of VIP in recirculating and in single pass isolated perfused rat liver (IPRL) preparations. Disappearance of added VIP was rapid in recirculating IPRL experiments with a half life of ca. 30 min. In single-pass steady-state studies in which livers were perfused at 16 ml/min for 30 min, clearance of VIP was complete (16 ml/min) at concentrations of 500 fmol/ml, but clearance fell to 3 and 1 ml/min at perfusate concentrations of 8 and 40 pmol/ml respectively. Further experiments to evaluate whether VIP was disappearing in perfusate itself demonstrated substantial metabolism of VIP in perfusate which had previously been circulated through a liver for 90 min. The products of metabolism were identical to those found in the IPRL. We conclude that VIP is rapidly cleared as it passes through the isolated perfused rat liver model with a significant proportion of clearance attributable to release of a peptidase from the liver into the perfusate.     

Release of vasoactive intestinal polypeptide by electrical field stimulation of rabbit ileum

The release of vasoactive intestinal polypeptide (VIP) induced by electrical field stimulation (EFS) of rabbit ileum was studied in vitro. EFS parallel to the muscularis propria caused a significant increase in VIP concentration in the buffer bathing the serosal surface of full-thickness ileum. This effect was blocked by 10^?7 M tetrodotoxin. When circular and longitudinal muscle was removed, the amount of measurable VIP in the tissue decreased to about one-half that of full-thickness ileum, and EFS no longer caused release of VIP into the serosal or mucosal buffers. Our data indicate that EFS of rabbit ileum causes release of VIP, presumably from VIP-containing nerves present in the tissue. These results support the idea that VIP may be a physiological neuroregulator of intestinal function.     

Neurogenic relaxation mediated by vasoactive intestinal polypeptide (VIP) in the isthmus of the human fallopian tube

The smooth musculature of the Fallopian tube is important for normal ovum transport, fertilization and implantation. Little is known about the factors controlling the motor activity of the isthmic sphincter. Studies were performed on smooth muscle preparations from the human tube in vitro. Electrical field stimulation of the nerves in the isthmic region reduced the motor activity, particularly in the circular muscle. The response was unaffected by adrenergic and cholinergic antagonists, but blocked by tetrodotoxin, suggesting a neural involvement. Vasoactive intestinal polypeptide (VIP) was considered a likely candidate for the neural mediation of this response in view of the high density of VIP-containing nerve fibres in this region, and in view of the fact that exogenous VIP causes a marked reduction of the tubal motor activity. To test whether VIP might be the endogenous mediator of this effect, nerve stimulation was carried out in the presence of large amounts of exogenous VIP in order to occupy all VIP receptors; the motor inhibitory action of VIP was counteracted by vasopressin. Under these conditions, nerve stimulation failed to reduce isthmic motor activity. This was not due to vasopressin since reduction occurred in the presence of this peptide alone. The results suggest that VIP is responsible for the neurogenic inhibition of motor activity in the isthmus region of the human Fallopian tube.     

Meal stimulated levels of pancreatic polypeptide (PP) and vasoactive intestinal polypeptide (VIP) in gastroplasty for morbid obesity

Plasma concentrations of pancreatic polypeptide (PP) and vasoactive intestinal polypeptide (VIP) were measured after a meal consisting of 11 ml meat extract and 40 ml of 20% soya oil in 11 patients before and 3 months after gastroplasty for morbid obesity. Gastroplasty results in a small proximal pouch with a narrow stoma allowing delayed emptying into the distal pouch, and consequently postprandial distension of the proximal pouch. Postprandial plasma PP increased significantly (P less than 0.01) independent of gastroplasty. PP is therefore not involved in the early satiety after gastroplasty. Postprandial plasma VIP increased significantly from fasting levels both before and after gastroplasty (P less than 0.05). Only 10 min after a meal, the median value of VIP was significantly higher after than before gastroplasty (P less than 0.02) and may be caused by distension of the proximal pouch.     

The distribution and cellular origin of vasoactive intestinal polypeptide in the avian gastrointestinal tract and pancreas

Summary The distribution and origins of vasoactive intestinal peptide (VIP) in the gut and pancreas of the turkey were studied by radioimmunoassay of tissue extracts and by immunocytochemistry. Several antisera were used that vary in their specificity for different regions of porcine or chicken VIP. Radioimmunoassays using NH₂-terminal specific antisera that react almost equally with porcine and chicken VIP's revealed significant amounts of immunoreactive VIP in extracts of pancreas, brain and all regions of the gastrointestinal tract from crop to colon. Highest concentrations (300pmol/g) were found in the colon muscle, and concentrations were generally low (< 20 pmol/g) in the mucosal layers of the small intestine. After ion exchange chromatography of extracts on CM-Sephadex three immunoreactive forms of VIP were separated corresponding to the three molecular forms previously found in mammalian gut extracts. In immunocytochemical studies nerve fibres were found throughout the gut, and in the pancreas. Immunoreactive nerve cell bodies were also identified in the submucous plexus throughout the gut, but were particularly prominent in the oesophagus and pancreas. It has previously been shown that VIP is a strong stimulant of the flow of pancreatic juice in birds whereas the structurally related hormone secretin, which is known to control the flow of pancreatic juice in mammals, is a weak stimulant. It is proposed that in birds VIP might regulate the pancreas, and other aspects of gut function, as a neurotransmitter or neurohormone.     

Prostaglandin D2 stimulates vasoactive intestinal polypeptide release into rat hypophysial portal blood

The effect of prostaglandin D2 (PGD2) on vasoactive intestinal polypeptide (VIP) release from the hypothalamus was examined by determining plasma VIP levels in rat hypophysial portal blood. Intraventricular injection of PGD2 (5 micrograms/rat) caused a 3-fold increase in the concentration of plasma VIP in hypophysial portal blood in anesthetized rats. A PGD2 metabolite, 13,14-dihydro-15-keto PGD2, did not affect VIP levels in portal blood. The flow rate of hypophysial portal blood was not changed after the injection of PGD2. The intraventricular injection of PGD2, but not PGD2 metabolite, resulted in an increase in peripheral plasma prolactin (PRL) levels in the rat. These findings suggest that PGD2 plays a stimulatory role in regulating VIP release from the hypothalamus into hypophysial portal blood and causes PRL secretion from the pituitary in rats.